Biocentury Emerging Company Profile - Accession: precisely targeted oncolytic viruses
Bent Jakobsen’s newest biotech is replacing the virus’ natural tropisms with an integrin-based cancer targeting mechanism - read the article by Richard Guy, Biopharma Analyst, here >
Commentaires